Difference between revisions of "Team:Toronto/Safety"
| (20 intermediate revisions by 2 users not shown) | |||
| Line 9: | Line 9: | ||
</html> | </html> | ||
{{Toronto/head}} | {{Toronto/head}} | ||
| + | <html> | ||
| + | </html> | ||
| + | {{Toronto/navbar-dark-cyan}} | ||
<html> | <html> | ||
| − | <div | + | <!-- Header div --> |
| − | + | <div class="section"> | |
| − | + | <div class="container header" id="dark-cyan"> | |
| − | + | <h1>Safety</h1> | |
| − | + | <p>Safety is the number one priority</p> | |
| − | + | </div> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | < | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | <div class=" | + | |
| − | + | ||
| − | <p> | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
| + | |||
| + | <!-- Content div --> | ||
| + | <div class="section bg-white"> | ||
| + | <div class="container content-page row"> | ||
| + | <div class="block content"> | ||
| + | |||
| + | <!-- subsection 1 --> | ||
| + | <div id="subsection-general" class="subsection"> | ||
| + | |||
| + | <h2>General Lab Safety</h2> | ||
| + | |||
| + | <p>Before starting the project, our team completed the biosafety and the biosecurity trainings provided by the University of Toronto Biosafety office, and our project supervisor, Dr. Radhakrishnan Mahadevan. The training modules completed include lab access and rules, biosafety levels and equipment, emergency procedures etc.</p> | ||
| + | <p>Overall, our team adhered to the Canadian Biosafety Standards and Guidelines.<sup><a href="#ref1">[1]</a></sup> The biosafety of our lab was overseen by the University's Institutional Biosafety Committee, with administrative and technical support provided by the Biosafety Team in the Office of Environmental Health and Safety.<sup><a href="#ref2">[2]</a></sup></p> | ||
| + | |||
| + | <!-- Multiple figure --> | ||
| + | <figure> | ||
| + | <div class="figures"> | ||
| + | <div class="image"><img src="https://static.igem.org/mediawiki/2017/0/0e/T--Toronto--2017_safety-3.jpg" alt="data" width="200px"></div> | ||
| + | <div class="image"><img src="https://static.igem.org/mediawiki/2017/9/91/T--Toronto--2017_wetlab-header.jpg" alt="data" width="200px"></div> | ||
| + | </div> | ||
| + | <figcaption>Lab safety is lab fun.</figcaption> | ||
| + | </figure> | ||
| + | <!-- Multiple figure END --> | ||
| + | |||
| + | </div> | ||
| + | <!-- subsection 1 END --> | ||
| + | |||
| + | <!-- subsection 2 --> | ||
| + | <div id="subsection-design" class="subsection"> | ||
| + | <h2>Safe Project Design</h2> | ||
| + | <p>All the biological materials were handled in open bench areas. Escherichia coli (E.coli) was the chassis organism used in our study, which is exempt from the requirements of the NIH Guidelines<sup><a href="#ref3">[3]</a></sup>, as a risk group 1 organism<sup><a href="#ref4">[4]</a></sup> . We fused the protein binding domain of LacI (from E.coli) and the light oxygen voltage domain (LOV) of Avena sativa.</p> | ||
| + | <p>We used a <span class="text-red">CI repressor</span> protein from Escherichia phage lambda in our switch. This sequence was obtained from a peer-reviewed article and has no indication of hazardous impact on eukaryotic cell lines.</p> | ||
| + | <p>The anti-CRISPR protein, <span class="text-red">AcrIIA4</span>, was obtained from Listeria monocytogenes prophages (risk group 1). The protein has been expressed in both bacterial and human cell lines in literature with no measurable toxicity.</p> | ||
| + | <p>The anti-microbial resistance factors in our project were <span class="text-red">Standard Kanamycin</span> and <span class="text-red">Chloramphenicol</span> resistance casettes, which are commonly used in research and pose little health risk.</p> | ||
| + | <p>Our engineered system does not have any risk to humans or the environment since our <span class="text-red">Cas9</span> protein only targets metabolic genes like <span class="text-red">araC</span> in E.Coli as well as reporter genes like <span class="text-red">GFP</span> or <span class="text-red">mCherry</span>. Standard decontamination and containment through thermal sterilization and certified waste disposal would also mitigate any potential release in the environment.</p> | ||
| + | </div> | ||
| + | <!-- subsection 2 END --> | ||
| + | |||
| + | <!-- subsection 3 --> | ||
| + | <div id="subsection-future" class="subsection"> | ||
| + | <h2>Future Considerations</h2> | ||
| + | <p>In terms of future applications, temporal control of Cas9 activity through our switch could reduce off-target edits and increase the fidelity of genomic integrations through homology-directed repair, which should improve the safety of this technology. Although, from an ethical standpoint, there are several key shareholders including patients, medical practitioners and legislative and executive agencies that could be impacted by human gene editing. Thus, we conducted a systematic analysis of the considerations of each of those groups through interviews and a collaborative podcast series.</p> | ||
| + | </div> | ||
| + | <!-- subsection 3 END --> | ||
| + | |||
| + | <hr> | ||
| + | <!-- Reference Subsection --> | ||
| + | <div id="content-yellow" class="subsection"> | ||
| + | <h2 class="text-cyan">References</h2> | ||
| + | <ol> | ||
| + | <li id="ref1">Canadian Biosafety Standards and Guidelines - <a href="https://www.canada.ca/en/public-health/services/canadian-biosafety-standards-guidelines.html">https://www.canada.ca/en/public-health/services/canadian-biosafety-standards-guidelines.html</a></li> | ||
| + | <li id="ref2">Biosafety Team in the Office of Environmental Health and Safety - <a href="https://ehs.utoronto.ca/our-services/biosafety/">https://ehs.utoronto.ca/our-services/biosafety/</a></li> | ||
| + | <li id="ref3">NIH Guidelines - <a href="https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment.html">https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment.html</a></li> | ||
| + | <li id="ref4">iGEM Risk Groups - <a href="https://2017.igem.org/Safety/Risk_Groups">https://2017.igem.org/Safety/Risk_Groups</a></li> | ||
| + | </ol> | ||
| + | </div> | ||
| + | <!-- Reference Subsection END --> | ||
| + | |||
| + | </div> | ||
| + | |||
| + | <!-- Sidebar --> | ||
| + | <div class="block sidebar"> | ||
| + | <div id="sidebar-box"> | ||
| + | <h3>Contents</h3> | ||
| + | <div class="sidebar-minibox"> | ||
| + | <ul></ul> | ||
| + | </div> | ||
| + | <h3>Related Pages</h3> | ||
| + | <div class="sidebar-minibox"> | ||
| + | <ul> | ||
| + | <li> <a href="https://2017.igem.org/Team:Toronto/Design">Design</a></li> | ||
| + | <li> <a href="https://2017.igem.org/Team:Toronto/Description">Description</a></li> | ||
| + | <li> <a href="https://2017.igem.org/Team:Toronto/Parts">Parts</a></li> | ||
| + | <li> <a href="https://2017.igem.org/Team:Toronto/Experiments">Experiments</a></li> | ||
| + | </ul> | ||
| + | </div> | ||
| + | </div> | ||
| + | </div> | ||
| + | <!-- Sidebar END --> | ||
| + | |||
| + | </div> | ||
</div> | </div> | ||
| + | |||
| + | |||
</html> | </html> | ||
{{Toronto/footer}} | {{Toronto/footer}} | ||
Latest revision as of 19:48, 14 December 2017
Safety
Safety is the number one priority
General Lab Safety
Before starting the project, our team completed the biosafety and the biosecurity trainings provided by the University of Toronto Biosafety office, and our project supervisor, Dr. Radhakrishnan Mahadevan. The training modules completed include lab access and rules, biosafety levels and equipment, emergency procedures etc.
Overall, our team adhered to the Canadian Biosafety Standards and Guidelines.[1] The biosafety of our lab was overseen by the University's Institutional Biosafety Committee, with administrative and technical support provided by the Biosafety Team in the Office of Environmental Health and Safety.[2]
Safe Project Design
All the biological materials were handled in open bench areas. Escherichia coli (E.coli) was the chassis organism used in our study, which is exempt from the requirements of the NIH Guidelines[3], as a risk group 1 organism[4] . We fused the protein binding domain of LacI (from E.coli) and the light oxygen voltage domain (LOV) of Avena sativa.
We used a CI repressor protein from Escherichia phage lambda in our switch. This sequence was obtained from a peer-reviewed article and has no indication of hazardous impact on eukaryotic cell lines.
The anti-CRISPR protein, AcrIIA4, was obtained from Listeria monocytogenes prophages (risk group 1). The protein has been expressed in both bacterial and human cell lines in literature with no measurable toxicity.
The anti-microbial resistance factors in our project were Standard Kanamycin and Chloramphenicol resistance casettes, which are commonly used in research and pose little health risk.
Our engineered system does not have any risk to humans or the environment since our Cas9 protein only targets metabolic genes like araC in E.Coli as well as reporter genes like GFP or mCherry. Standard decontamination and containment through thermal sterilization and certified waste disposal would also mitigate any potential release in the environment.
Future Considerations
In terms of future applications, temporal control of Cas9 activity through our switch could reduce off-target edits and increase the fidelity of genomic integrations through homology-directed repair, which should improve the safety of this technology. Although, from an ethical standpoint, there are several key shareholders including patients, medical practitioners and legislative and executive agencies that could be impacted by human gene editing. Thus, we conducted a systematic analysis of the considerations of each of those groups through interviews and a collaborative podcast series.
References
- Canadian Biosafety Standards and Guidelines - https://www.canada.ca/en/public-health/services/canadian-biosafety-standards-guidelines.html
- Biosafety Team in the Office of Environmental Health and Safety - https://ehs.utoronto.ca/our-services/biosafety/
- NIH Guidelines - https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment.html
- iGEM Risk Groups - https://2017.igem.org/Safety/Risk_Groups
